CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

NCT04156256 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Hematologic Malignancy
Acute Myeloid Leukemia
Myelodysplastic Syndromes
Myeloproliferative Neoplasm
Chronic Myeloid Leukemia

Interventions

BIOLOGICAL: CD123-CD33 cCAR T cells

Sponsor

iCell Gene Therapeutics

Collaborators

[object Object]
[object Object]
[object Object]